Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

abstract：:Mouse colon adenocarcinoma Co38 is widely used as a screening model for human colon tumors. To understand better the influence of tumor size on the main drug-metabolizing enzyme systems, we tested 15 mouse Co38 tumors at different sizes. The average weight was 917 +/- 444 mg (range, 300-1,400 mg). Cytochromes P-450 (1...

journal_title：Cancer chemotherapy and pharmacology

authors： Massaad L,Chabot GG,Toussaint C,Koscielny S,Morizet J,Bissery MC,Gouyette A

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND:The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors. DESIGN:FOLFIRI + flavopiridol were administered every 2 weeks. Based on sequence-dependent inhibition, f...

journal_title：Cancer chemotherapy and pharmacology

authors： Dickson MA,Shah MA,Rathkopf D,Tse A,Carvajal RD,Wu N,Lefkowitz RA,Gonen M,Cane LM,Dials HJ,Schwartz GK

更新日期：2010-11-01 00:00:00

abstract：:Experimental data suggest that multidrug resistance in cancer may be overcome by using an increased dose of anticancer agent(s) in combination with a resistance-modifying agent (RMA). We studied the pharmacokinetics and metabolism of both epirubicin (EPI) and verapamil (VPL) to explore the possible pharmacokinetic int...

journal_title：Cancer chemotherapy and pharmacology

authors： Mross K,Hamm K,Hossfeld DK

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. PATIENTS AND METHODS:A total of 104 consecutive patients were enrolled for treatment with FA 100 mg/m(2) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Francini G,Petrioli R,Messinese S,Pozzessere D,Marsili S,Correale P,Sabatino M,Fiaschi AI

更新日期：2002-10-01 00:00:00

abstract：PURPOSE:miRNAs are implicated in drug resistance of multiple cancers including non-small cell lung cancer (NSCLC), highlighting the potential of miRNAs as chemoresistance regulators in cancer treatment. This study aims to explore the relationship between miR-181c and chemoresistance of NSCLC cells. METHODS:qRT-PCR was...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang H,Hu B,Wang Z,Zhang F,Wei H,Li L

更新日期：2017-11-01 00:00:00

abstract：:Leucovorin requirements for protection of the T cell line CCRF-CEM and the B cell line LAZ-007 against the cytotoxic effects of a variety of antifolates were studied. Differential leucovorin protection for DDMP-induced growth suppression occurred in the opposite direction to that for MTX, with CCRF-CEM requiring less ...

journal_title：Cancer chemotherapy and pharmacology

authors： Browman GP,Spiegl P,Booker L,Rosowsky A

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia (CLL), a disease predominantly of the elderly. We sought to determine whether age, renal function or pretreatment hematologic status predicted toxicity of fludarabine treatment for CLL. METHODS:We evaluated ...

journal_title：Cancer chemotherapy and pharmacology

authors： Martell RE,Peterson BL,Cohen HJ,Petros WP,Rai KR,Morrison VA,Elias L,Shepherd L,Hines J,Larson RA,Schiffer CA,Hurwitz HI

更新日期：2002-07-01 00:00:00

abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosso R,Alama A,Repetto L,Conte PF

更新日期：1990-01-01 00:00:00

abstract：:Clinical evidence suggests some lack of cross resistance between vincristine (VCR) and vindesine (VDS). To investigate this phenomenon experimentally, drug-resistant L5178Y lymphoblast cell lines have been derived in vitro. These lines, under conditions of continuous drug exposure, exhibit a 50-fold order of resistanc...

journal_title：Cancer chemotherapy and pharmacology

authors： Hill BT,Whelan RD

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:S-1 has a favorable effect in unresectable pancreatic cancer and a potential radiosensitizer. In addition, daily oral administration of S-1 is more convenient than continuous infusion of 5-fluorouracil. This study was designed to evaluate the efficacy and safety of S-1 and concurrent radiotherapy in patients wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Kim HM,Bang S,Park JY,Seong J,Song SY,Chung JB,Park SW

更新日期：2009-02-01 00:00:00

abstract：PURPOSE:Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic age...

journal_title：Cancer chemotherapy and pharmacology

authors： Wei J,Liu B,Wang L,Qian X,Ding Y,Yu L

更新日期：2007-10-01 00:00:00

abstract：PURPOSE:In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of...

journal_title：Cancer chemotherapy and pharmacology

authors： Dowlati A,Levitan N,Gordon NH,Hoppel CL,Gosky DM,Remick SC,Ingalls ST,Berger SJ,Berger NA

更新日期：2001-01-01 00:00:00

abstract：:Over the last decade, metronomic chemotherapy has been increasingly considered as an attractive strategy for treating cancer in a variety of settings. Beside pharmaco-economic considerations making metronomics a unique opportunity in low- or middle-income countries, revisiting dosing schedules using continuous low dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Barbolosi D,Ciccolini J,Meille C,Elharrar X,Faivre C,Lacarelle B,André N,Barlesi F

更新日期：2014-09-01 00:00:00

abstract：PURPOSE:The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in reducing 5-fluorouracil (FUra) host-toxicity and enhancing its chemotherapeutic efficacy against human colon tumors. PTAU is a potent and specific inhibitor of uridine phosphorylase (UrdPase, EC 2.4...

journal_title：Cancer chemotherapy and pharmacology

authors： Al Safarjalani ON,Rais R,Shi J,Schinazi RF,Naguib FN,el Kouni MH

更新日期：2006-11-01 00:00:00

abstract：BACKGROUND:Statins have potential antineoplastic properties via arrest of cell-cycle progression and induction of apoptosis. A previous study demonstrated in vitro and in vivo antineoplastic synergism between statins and gemcitabine. The present randomized, double-blinded, phase II trial compared the efficacy and safet...

journal_title：Cancer chemotherapy and pharmacology

authors： Hong JY,Nam EM,Lee J,Park JO,Lee SC,Song SY,Choi SH,Heo JS,Park SH,Lim HY,Kang WK,Park YS

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVES:ATP-binding cassette subfamily C member 4 (ABCC4) encoding MRP4 protein is involved in pediatric acute lymphoblastic leukemia (ALL) drug resistance. The nonsynonymous single nucleotide polymorphism (SNP) rs2274407 (G912T; K304N) is located in the 3' splice acceptor site of exon 8 of ABCC4 pre-mRNA. The aim o...

journal_title：Cancer chemotherapy and pharmacology

authors： Mesrian Tanha H,Rahgozar S,Mojtabavi Naeini M

更新日期：2017-07-01 00:00:00

abstract：PURPOSE:There is a need for effective chemotherapy protocols for gall bladder cancer (GBC). Gemcitabine has antitumor activity in pancreatic cancer. Oxaliplatin is effective in GI cancers. Based on evidence of synergy between these two, we designed this study to evaluate efficacy of this combination in unresectable GBC...

journal_title：Cancer chemotherapy and pharmacology

authors： Sharma A,Mohanti B,Raina V,Shukla N,Pal S,Dwary A,Deo S,Sahni P,Garg P,Thulkar S,DattaGupta S,Rath G

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:This study compared the pharmacokinetics of PF-06439535, a potential bevacizumab biosimilar, to bevacizumab sourced from the European Union (bevacizumab-EU) and USA (bevacizumab-US), and of bevacizumab-EU to bevacizumab-US. METHODS:In this double-blind study, 102 healthy males, aged 21-55 years, were randomize...

journal_title：Cancer chemotherapy and pharmacology

authors： Knight B,Rassam D,Liao S,Ewesuedo R

更新日期：2016-04-01 00:00:00

abstract：:We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementary chemotherapy, and, finally, active immunotherapy. The overall compl...

journal_title：Cancer chemotherapy and pharmacology

authors： Misset JL,Mathé G,Tubiana M,Caillou B,de Vassal F,Pouillart P,Gil M,Tentas C,Hayat M,Schwarzenberg L,Jasmin C,Delgado M,Machover D,Ribaud P,Musset M

更新日期：1978-01-01 00:00:00

abstract：PURPOSE:Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this st...

journal_title：Cancer chemotherapy and pharmacology

authors： Nio K,Arita S,Isobe T,Kusaba H,Kohashi K,Kajitani T,Tamura S,Hirano G,Mitsugi K,Makiyama A,Esaki T,Ariyama H,Oda Y,Akashi K,Baba E

更新日期：2015-04-01 00:00:00

abstract：:The effect of selenite coadministration on the toxicity and antitumor activity of repeated treatment with high doses of cis-diamminedichloroplatinum (cis-DDP) was examined in mice. Sodium selenite was injected s.c. into separate abdominal sites of mice together with cis-DDP at a molar ratio of 1:3.5 (selenite to cis-D...

journal_title：Cancer chemotherapy and pharmacology

authors： Satoh M,Naganuma A,Imura N

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:The dolastatins are a class of naturally occurring cytotoxic peptides which function by inhibiting microtubule assembly and tubulin polymerization. Cemadotin is a synthetic analogue of dolastatin 15 with potent antiproliferative and preclinical antitumor activity. This report describes a phase I study to evalua...

journal_title：Cancer chemotherapy and pharmacology

authors： Supko JG,Lynch TJ,Clark JW,Fram R,Allen LF,Velagapudi R,Kufe DW,Eder JP Jr

更新日期：2000-01-01 00:00:00

abstract：:Doxifluridine (5'-deoxy-5-fluorouridine, 5'-dFUR) metabolism has been reported to be saturable and associated with a fall in clearance of the drug as the dose is increased. The aim of the present study was to determine the disposition of 5'-dFUR and 5-fluorouracil (5-FU) when 5'-dFUR was given as a 5-day infusion, wit...

journal_title：Cancer chemotherapy and pharmacology

authors： Reece PA,Olver IN,Morris RG,Bishop JF,Guentert TW,Hill HS,Hillcoat BL

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:The diatomic radical nitric oxide (NO) has been the cause of intense debate with implication in carcinogenesis, tumour progression, invasion, angiogenesis and modulation of therapeutic responses. The tumour biology of NO is highly complex, and this review summarises the various protective and damaging mode of a...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh S,Gupta AK

更新日期：2011-06-01 00:00:00

abstract：PURPOSE:Anti-angiogenic agents combined with histone deacetylase inhibitors act synergistically in vitro and in vivo. We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. METHODS:Bevacizumab w...

journal_title：Cancer chemotherapy and pharmacology

authors： Wheler JJ,Janku F,Falchook GS,Jackson TL,Fu S,Naing A,Tsimberidou AM,Moulder SL,Hong DS,Yang H,Piha-Paul SA,Atkins JT,Garcia-Manero G,Kurzrock R

更新日期：2014-03-01 00:00:00

abstract：:Advanced recurrent squamous cell head and neck cancer patients were prospectively randomized to receive or not receive dibromodulcitol 10 mg/kg PO weekly for 8 consecutive weeks in addition to bleomycin chemotherapy. Patients initially entered in the study received bleomycin 15 mu/m2 three times weekly for 8 weeks. Th...

journal_title：Cancer chemotherapy and pharmacology

authors： Issell BF,Borsos G,D'Aoust JC,Banhidy F,Crooke ST,Eckhardt S

更新日期：1982-01-01 00:00:00

abstract：:We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

journal_title：Cancer chemotherapy and pharmacology

authors： Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

更新日期：1993-01-01 00:00:00

abstract：:The effect of acetazolamide (A.A.) on the antineoplastic activity of 1-phthalidyl 5-fluorouracil (PH-FU) against rat and mouse solid tumors was examined. A.A., an inhibitor of liver PH-FU hydrolase, had no antitumor activity but greatly enhanced the activity of PH-FU when coadministered. The potentiation was evaluated...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasai H,Tonda K,Hirata M

更新日期：1986-01-01 00:00:00

abstract：BACKGROUND:3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS:Twenty patients received one dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Chao J,Synold TW,Morgan RJ Jr,Kunos C,Longmate J,Lenz HJ,Lim D,Shibata S,Chung V,Stoller RG,Belani CP,Gandara DR,McNamara M,Gitlitz BJ,Lau DH,Ramalingam SS,Davies A,Espinoza-Delgado I,Newman EM,Yen Y

更新日期：2012-03-01 00:00:00

abstract：PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

journal_title：Cancer chemotherapy and pharmacology

authors： Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

更新日期：2010-02-01 00:00:00